2026 ICD-10-CM Diagnosis Code T36.5X5SAdverse effect of aminoglycosides, sequela
T36.5X5S is a billable ICD-10-CM diagnosis code for adverse effect of aminoglycosides, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T36.5X5S.
Present on Admission (POA)Billing
T36.5X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adverse reaction to chlorhexidine and/or neomycin
- Amikacin adverse reaction
- Aminoglycosides adverse reaction
- Antituberculous drug adverse reaction
- Gentamicin adverse reaction
- Kanamycin adverse reaction
- Neomycin adverse reaction
- Nephropathy induced by aminoglycoside
- Netilmicin adverse reaction
- Spectinomycin adverse reaction
- Streptomycin adverse reaction
- Tobramycin adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of systemic antibiotics (T36). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Amikacin
a broad-spectrum antibiotic derived from kanamycin. it is reno- and oto-toxic like the other aminoglycoside antibiotics.Kanamycin Kinase
a class of enzymes that inactivate aminocyclitol-aminoglycoside antibiotics (aminoglycosides) by regiospecific phosphorylation of the 3' and/or 5' hydroxyl.Dibekacin
analog of kanamycin with antitubercular as well as broad-spectrum antimicrobial properties.Framycetin
a component of neomycin that is produced by streptomyces fradiae. on hydrolysis it yields neamine and neobiosamine b. (from merck index, 11th ed)Kanamycin
antibiotic complex produced by streptomyces kanamyceticus from japanese soil. comprises 3 components: kanamycin a, the major component, and kanamycins b and c, the minor components.Kanamycin Resistance
nonsusceptibility of bacteria to the antibiotic kanamycin, which can bind to their 70s ribosomes and cause misreading of messenger rna.Netilmicin
semisynthetic 1-n-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.Novobiocin
an antibiotic compound derived from streptomyces niveus. it has a chemical structure similar to coumarin. novobiocin binds to dna gyrase, and blocks adenosine triphosphatase (atpase) activity. (from reynolds, martindale the extra pharmacopoeia, 30th ed, p189)Paromomycin
an aminoglycoside antibacterial and antiprotozoal agent produced by species of streptomyces.Ribostamycin
a broad-spectrum antimicrobial isolated from streptomyces ribosifidicus.Sisomicin
antibiotic produced by micromonospora inyoensis. it is closely related to gentamicin c1a, one of the components of the gentamicin complex (gentamicins).Spectinomycin
an antibiotic produced by streptomyces spectabilis. it is active against gram-negative bacteria and used for the treatment of gonorrhea.Tobramycin
an aminoglycoside, broad-spectrum antibiotic produced by streptomyces tenebrarius. it is effective against gram-negative bacteria, especially the pseudomonas species. it is a 10% component of the antibiotic complex, nebramycin, produced by the same species.Tobramycin, Dexamethasone Drug Combination
a topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T36.5X5S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T36.5X5SOverview
Is T36.5X5S (Adverse effect of aminoglycosides) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of aminoglycosides, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T36.5X5S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of aminoglycosides itself has resolved, not the original event.
What MS-DRG does T36.5X5S group to?
On inpatient claims, adverse effect of aminoglycosides, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T36.5X5S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of aminoglycosides, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T36.5X5S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of aminoglycosides, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
